Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 127, Issue 1, 2001, Pages 20-26

  Koyama, Shohei ^a   Koike, Naoto ^a   Adachi, Shinya ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Apoptosis; Fas ligand; Fas receptor; Gastric carcinoma; Immune privilege

Indexed keywords

FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; FAS RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; ADULT; AGED; ASCITES; BIOSYNTHESIS; CARCINOMA; CELL MEMBRANE; CELL SEPARATION; EPITHELIUM; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NICK END LABELING; STOMACH TUMOR; TUMOR ASSOCIATED LEUKOCYTE; CANCER INFILTRATION; CLINICAL ARTICLE; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; MALE; PARACRINE SIGNALING; QUANTITATIVE ASSAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; ASCITES; CARCINOMA; CELL MEMBRANE; CELL SEPARATION; EPITHELIUM; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 0034744323     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320000181     Document Type: Article

References (33)

1. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
2. A role for CD95 ligand in preventing graft rejection
3. Expression of Fas ligand by human gastric adenocareinomas: A potential mechanism of immune escape in stomach cancer
4. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (Apo-1/CD95) receptors and aberrant expression of functional Fas ligand
5. Regulation of the proinflammatory effects of the Fas ligand (CD95L)
6. Fas ligand-induced apoptosis as a mechanism of immune privilege
7. Melanoma cell expression of Fas (Apo CD95) ligand: Implication for tumor immune escape
8. HLA-class-1 restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer
9. Japanese classification of gastric carcinoma, 2nd edn.
10. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
11. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
12. Metalloproteinase-mediated release of human Fas ligand
13. Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma
14. Immunosuppressive effect of shedding intercellular adhesion molecule I antigen on cell-mediated cytotoxicity against tumor cells
15. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma
16. Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: Human glandular stomach as a site of immune privilege
17. Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma
18. Expression of costimulatory molecules B7-1 and B7-2 on human gastric carcinoma
19. Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: A two-color flow-cytometric analysis
20. Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events
21. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
22. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand
23. Apoptosis by death factor
24. The Fas death factor
25. Tumor necrosis factor-α and interferone-γ induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells
26. Human lung carcinoma express Fas ligand
27. Antitumor effect of locally produced CD95 ligand
28. Expression of Fas ligand in liver metastasis of human colonic adenocarcinomas
29. Lymphocyte apoptosis induced by CD95 (Apo-l/Fas) ligandexpressing tumor cells: A mechanism of immune evasion?
30. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes
31. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
32. Human tumor-infiltrating lymphocytes: A marker of host response
33. A cell-killing monoclonal antibody (ant-Fas) to a cell surface antigen co-downregulated with receptor of tumor necrosis factor